DNMT3A R882 mutations promote chemoresistance and residual disease in AML

Share :
Published: 12 Jun 2015
Views: 3111
Rating:
Save
Dr Olga Guryanova - Memorial Sloan Kettering Cancer Center, New York, USA

Dr Olga Guryanova presents, at a press conference at EHA 2015, the findings of her work looking at the role of mutant DNMT3A in acute myeloid leukaemia (AML) pathogenesis and chemoresistance.

Read the news story for more.